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Capsule Endoscopy in Inﬂammatory Bowel Disease Type
Unclassiﬁed and Indeterminate Colitis Serologically Negative
Sandra Lopes, MD, Pedro Figueiredo, MD, PhD, Francisco Portela, MD, Paulo Freire, MD, Nuno
Almeida, MD, Clotilde Le´rias, MD, Hermano Gouveia, MD, and Maximino Correia Leita˜o, MD, PhD
Background: The value of capsule endoscopy in the setting of
inﬂammatory bowel disease type unclassiﬁed (IBDU) and indeter-
minate colitis (IC) remains obscure. The aim was to evaluate the
clinical impact of capsule endoscopy on IBDU/IC patients with
negative serology.
Methods: Eighteen patients with long-standing IBDU (n ¼ 14)
and IC (n ¼ 4) were enrolled to undergo a capsule endoscopy
and then followed prospectively. Lesions considered diagnostic of
Crohn’s disease (CD) were 4 or more erosions/ulcers and/or a
stricture. The median follow-up time after capsule endoscopy was
32 6 11 months (23–54 months).
Results: Total enteroscopy was possible in all patients. In 2
patients the examination was normal (Group 1). In 9 patients subtle
ﬁndings were observed (Group 2): focal villi denudation (n ¼ 1)
and fewer than 4 erosions/ulcers (n ¼ 8). In 7 patients, 4 or more
erosions/ulcers were detected (Group 3), leading to a diagnosis of
CD. However, their treatment was not reassessed on the basis of the
capsule ﬁndings. Until now, a deﬁnitive diagnosis has been
achieved in 2 additional patients: 1 from Group 1 (ulcerative colitis)
and another patient from Group 2 (CD), who began inﬂiximab infu-
sions. Nine patients remained indeterminate at follow-up.
Conclusions: Although capsule endoscopy enabled the diagnosis
of CD in 7 patients, in none of them was the clinical management
changed. Moreover, a change in therapy due to a diagnosis of CD
was made for only 1 patient, who presented nonspeciﬁc ﬁndings.
Our results suggest that capsule ﬁndings are not helpful in the
work-up of these patients.
(Inﬂamm Bowel Dis 2010;16:1663–1668)
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T he distinction between Crohn’s disease (CD) and ulcer-ative colitis (UC) is supported by clinical, radiological,
endoscopic, and pathological information.1 Unfortunately,
in 10%–15% of patients the distinction cannot be made
easily, so that the term indeterminate colitis (IC) has been
adopted in such cases.2 However, the term has been used
with different deﬁnitions, leading to considerable confu-
sion.3 Following the report of the Montreal Working Party
in 2005, it was proposed that the term indeterminate colitis
should be reserved for cases in which a surgical specimen
is available, while the term inﬂammatory bowel disease
type unclassiﬁed (IBDU) should be used for patients who
present divergent clinical, endoscopic, and histological fea-
tures and for whom no surgical specimen is available.2,4
The deﬁnition of IBDU is not merely for academic pur-
poses, as epidemiological data have shown that the clinical
course and prognosis of IBDU can be worse than UC, par-
ticularly because of the higher rate of pouch failure and
long-term complications.2
The measurement of serological markers such as
anti-Saccharomyces cerevisiae (ASCA) and perinuclear
anti-neutrophil cytoplasmic antibodies (pANCA) has been
proposed as a method to differentiate CD from UC. Joos-
sens et al5 performed a prospective study to determine
whether ASCA or pANCA may be useful in classifying
patients with IBDU. Results of this study have demon-
strated that serological markers may be helpful in predict-
ing the course of patients with IBDU. However, patients
with an initial diagnosis of IBDU and negative serology
were more likely to remain indeterminate and it was pro-
posed that these patients may reﬂect a distinct clinicosero-
logical subgroup of inﬂammatory bowel disease (IBD).
Capsule endoscopy (CE) has revolutionized the study
of the small bowel by providing a reliable method to endo-
scopically evaluate the entire small bowel. The available
data suggest that CE can identify small-bowel mucosal
lesions not observed through other imaging techniques and
it may therefore play an important diagnostic role in the
evaluation of some patients with known or suspected CD.6
Several studies have examined the potential role of CE in
the setting of IBDU/IC, suggesting that CE is useful in the
work-up of these patients by ruling out small-bowel lesions
suggestive of CD.6–8 Despite these new developments, a
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long-term follow-up is often the only way to determine the
correct diagnosis.
The aim of our study is to evaluate the clinical
impact of CE on long-standing IBDU and IC patients with
negative serology. We focused on these patients because
there is less information available on this subgroup of IBD,




Eighteen consecutive patients with long-standing
IBDU/IC and negative serology were selected. They were
included in our study from 2004, undergoing a CE exami-
nation, and then followed until the present time (mean fol-
low-up of 31.6 6 10.6 months).
The IBDU group consisted of 14 patients (7 females,
mean age 40 6 12 years), with a duration of disease of 5.8
6 3.3 years (2.5–16 years), whose clinical course did not
show correspondence between clinical, endoscopic, and
histological features. The IC group consisted of 4 patients
(2 females, mean age 41 6 6 years) with a duration of dis-
ease of 8.9 6 5.5 years (2–10.5 years) for whom a surgical
specimen was available.
Data were collected by reviewing the clinical records
including age, sex, clinical presentation, endoscopic and
pathological features, serological results, and past and cur-
rent medication. The patients’ characteristics are shown in
Tables 1 and 2. Seven patients had previously been treated
with azathioprine/6-mercaptopurine, cyclosporine, or inﬂix-
imab (Tables 1, 2).
They showed no evidence of obstructive symptoms
and were not taking nonsteroidal antiinﬂammatory drugs
(NSAIDs), aspirin, clopidogrel, or warfarin in the month
prior to the examination. None of the CE examinations was
conducted during hospitalization or disease exacerbation. A
previous examination of the small bowel (standard ileo-
scopy or radiology) was negative in all cases.
CE Procedure
A PillCam SB (Given Imaging, Yoqneam, Israel) was
used. The patients fasted for 12 hours before the examina-
tion. Approximately 10 minutes before ingestion of the
capsule 10 mg of metoclopramide was taken orally. The
capsule was swallowed with a glass of water containing
simethicone. All patients were advised to start drinking
water after 2 hours and to have a liquid meal 4 hours after
capsule ingestion. After 8 hours the sensor array and the
recording device were removed. The digital video image
streams of the examinations were downloaded into the
RAPID system. The images were then visualized by 2
observers, using the CE structured terminology9 and were
described according to the following classiﬁcation.
Outcome Measures
Lesions considered diagnostic of CD by CE were 4
or more erosions/ulcers (Fig. 1) and/or the presence of a
stricture, and these patients were classiﬁed as Group 3.
Patients presenting subtle ﬁndings such as focal villi denu-
dation (Fig. 2), isolated erosion (Fig. 3), or fewer than 4
erosions/ulcers were considered to belong to Group 2. A
normal examination (Fig. 4) was described as Group 1.
We assumed a deﬁnitive diagnosis when the disease
evolved to the point that a diagnosis of CD or UC was ren-
dered by new data obtained from clinical, laboratory, radio-
logical, endoscopic (including the CE ﬁndings), and patho-
logical information.
CD was deﬁnitively diagnosed when there was char-
acteristic small-bowel involvement, when ﬁstula occurred,
or when granulomas were found at biopsy.1 Small-bowel
involvement was recognized by the presence of lesions sep-
arated by normal mucosa, transmural involvement with ﬁs-
suring ulcers, and ﬁstula and development of strictures.1
Small-bowel lesions were deﬁned as so-called ‘‘typical
ulcerations’’ corresponding to excavated lesions (erosions
and ulcers) described in the CE structured terminology.9
Mow et al13 described ulcers as white lesions within a cra-
ter and with surrounding erythema, whereas superﬁcial
white lesions with surrounding erythema were character-
ized as erosions.


















1 M/32 Nonspeciﬁc Nonspeciﬁc UC like IS Group1 UC 54 Surgery
2 M/45 CD like Nonspeciﬁc UC like IS Group1 IC 48 5ASA
3 F/37 Nonspeciﬁc UC like UC like IS Group2 IC 25 None
4 F/44 Nonspeciﬁc Nonspeciﬁc UC like IS Group3 CD 24 5ASA
IS, immunosuppressive drugs; 5ASA, mesalamine.
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The deﬁnitive diagnosis of UC was based on a surgi-
cal specimen with diffuse involvement starting distally and
with an absence of transmural inﬂammation. For cases in
which only endoscopic samples were available the diagno-
sis was based on diffuse colonic inﬂammation, distally
more intense, and normal small-bowel mucosa.1
Ethical Considerations
Informed consent was obtained from all patients.
None of the authors have any conﬂict of interest to report.
RESULTS
The capsule reached the cecum in all patients. Me-
dian gastric transit time and small-bowel transit time were
31.6 6 17 minutes (3–90) and 3.5 6 1.6 hours (1.51–
7.47), respectively. The procedure was well tolerated and
there were no cases of capsule retention or any other
adverse event.
The examination was normal in 2 patients (Group 1).
Pathological ﬁndings detected in the other 16 patients were
limited to the mid-small bowel (jejunum and proximal


















1 F/32 Nonspeciﬁc CD like UC like IS Group2 CD 31 AZTþIFX
2 F/39 UC like CD like UC like 5ASA* Group2 IBDU 30 None
3 M/48 CD like UC like UC like IS Group2 IBDU 31 IFX
4 F/59 UC like UC like Nonspeciﬁc IS Group2 IBDU 7 MTXþ5ASA
5 F/20 CD like Nonspeciﬁc CD like IS Group2 IBDU 33 IFX
6 M/57 UC like Nonspeciﬁc Nonspeciﬁc 5ASA* Group2 IBDU 26 5ASA
7 M/32 CD like Nonspeciﬁc Nonspeciﬁc 5ASA Group2 IBDU 31 5ASA
8 F/28 UC like Nonspeciﬁc UC like IS Group2 IBDU 30 AZTþ5ASA
9 F/31 UC like Nonspeciﬁc Nonspeciﬁc 5ASA* Group3 CD 31 Budesonide
10 F/32 Nonspeciﬁc CD like UC like IS Group3 CD 31 6MPþ5ASA
11 F/26 UC like UC like Nonspeciﬁc 5ASA Group3 CD 31 5ASA
12 F/53 Nonspeciﬁc Nonspeciﬁc Nonspeciﬁc 5ASA Group3 CD 48 5ASA
13 M/35 Nonspeciﬁc CD like Nonspeciﬁc 5ASA Group3 CD 31 None
14 M/50 UC like Nonspeciﬁc Nonspeciﬁc 5ASA Group3 CD 31 5ASA
*Under mesalamine but needs steroids intermittently for disease control.5ASA, mesalamine; IS, immunosuppressive drugs; 6-MP, 6-mercaptopurine; IFX,
inﬂiximab; MTX, methotrexate; AZT, azathioprine.
FIGURE 1. Capsule endoscopic diagnostic ﬁndings such
as an ulcer (described as Group 3). [Color ﬁgure can be
viewed in the online issue, which is available at
wileyonlinelibrary.com.]
FIGURE 2. Capsule endoscopic subtle ﬁndings such as
focal villi denudation (described as Group 2). [Color ﬁgure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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ileum) in 8 cases, to the distal small-bowel or terminal il-
eum in 1, and throughout the entire small bowel in 7 cases.
In 9 patients subtle ﬁndings were observed (Group 2): focal
villi denudation in 1 patient, isolated erosion in another
patient, and fewer than 4 erosions/ulcers, with a median of
2 lesions, in the remaining 7 patients (Table 3). In 7
patients CE detected signiﬁcant lesions (Group 3) leading
to a CD diagnosis: 4 ulcers in 1 patient, 6 or more erosions
(a median of 8) in 3 patients, and ﬁnally, both ulcers and
erosions (a median of 7 and 38, respectively) in the
remaining 3 patients (Table 3). Besides the capsule ﬁnd-
ings, the clinical strategy was maintained in these last 7
patients: 4 of them are taking mesalamine, 1 is being
treated with budesonide, 1 is being kept on 6-mercaptopur-
ine, and the last is asymptomatic without medication.
Despite a nonspeciﬁc or a negative CE, a deﬁnitive
diagnosis was achieved in 2 additional patients after a
mean duration of disease of 6 years. CD was diagnosed in
1 case from Group 2, 1 month after CE, in relation to the
emergence of a rectovaginal ﬁstula in distal colitis with
rectal sparing. This patient was reassessed and started on
inﬂiximab infusions. In another case, UC was diagnosed
following proctocolectomy performed 1 year after a nega-
tive CE in a Group 1 patient who had previously been sub-
mitted to a subtotal colectomy to treat a toxic megacolon.
Nine patients remain with a diagnosis of IBDU/IC with
a mean disease duration of 9.6 6 4 years (5–17). Of these 9, 8
patients are from Group 2 and 1 from Group 1: 3 are taking
mesalamine, 2 maintain inﬂiximab infusions, 2 are being kept
on azathioprine and methotrexate, respectively, and the last 2
patients are asymptomatic without medication.
DISCUSSION
CE can detect mucosal inﬂammatory changes of the
small intestine often missed by other imaging techniques.
In a pooled data analysis, CE had a miss rate for ulcers of
only 1%.10 Moreover, a meta-analysis comparing CE to
other imaging methods to observe the small bowel for IBD
has established that CE has an incremental diagnostic yield
of 25%–40% superior to that of other techniques.11 On the
other hand, published reports on the yield of CE are condi-
tioned by the lack of a validated CE scoring index that
would allow the presence of CD to be predicted.12 Mow et
al13 used the empirical cutoff of 3 ulcers of any size at CE
to establish a diagnosis of CD, but Fidder et al14 deﬁned a
positive capsule study for CD by the presence of 4 or more
ulcers, erosions, or a region with clear exudate and muco-
sal hyperemia and edema. Buchman et al15 graded CE vid-
eos as grade 0 (normal), grade 1 (erythema, isolated villi
loss), grade 2 (erosion, no ulcer), or grade 3 (ulcers, spon-
taneous bleeding and/or stricture). Gal et al16 divided the
small bowel into 2 on the basis of small-bowel transit time
and rated each segment for 3 components: an inﬂammation
score, an extent of disease score, and a narrowing score.
More recently, Gralnek et al17 created a scoring index
based on 3 capsule endoscopic variables: villous appear-
ance, ulcers, and stenosis. The number of lesions was
deﬁned as single, few (2–7 lesions), or multiple (8 or more
lesions). A score below 135 is classiﬁed as normal or clini-
cally insigniﬁcant mucosal inﬂammatory change and a
score higher than 790 is classiﬁed as moderate to severe.
It must be remembered, however, that there are path-
ological conditions in which small-bowel permeability is
FIGURE 3. Capsule endoscopic subtle ﬁndings such as
isolated erosion (described as Group 2). [Color ﬁgure can
be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
FIGURE 4. Small-bowel mucosa with no alteration
(described as Group 1). [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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increased and that all these conditions may have small in-
testinal erosions and ulcers. They include NSAID intake,
lymphoid hyperplasia, lymphoma, radiation enteritis,
human immunodeﬁciency virus with opportunistic infec-
tion, intestinal tuberculosis, and Behc¸et’s disease.18 There-
fore, it is important to exclude all these pathological condi-
tions before a ﬁnal diagnosis of CD is made. Until now,
none of the above-mentioned conditions has been diag-
nosed in our patients. On the other hand, Goldstein et al19
reported that 11% of healthy volunteers had small-intestine
mucosal breaks, even in the absence of NSAID intake.
Graham et al20 showed that the most severe damage among
the nonusers of NSAID controls was 1 small erosion, none
of them having 4 or more erosions. These results led us to
consider 4 or more erosions/ulcers, or the presence of a
stricture, as lesions diagnostic of small-bowel CD. A limi-
tation of our study is the absence of a control group of
asymptomatic UC patients to be used as a reference in
order to ascertain the baseline frequency of small-bowel
lesions in such patients. However, in clinical practice rou-
tine evaluation of the small bowel by CE in asymptomatic
patients is not indicated and, therefore, CE may be most
clinically useful in a setting in which UC is refractory to
medical treatment, or when presenting atypical clinical fea-
tures, as well as in the case of previous colectomy.21
Approximately 10% of patients with an initial diagnosis of
UC will be reclassiﬁed as having either CD or IBDU at
follow-up.21 In 1 retrospective study, 19 patients out of
120 (16%), with an established diagnosis of UC and atypi-
cal symptoms (10%), or with medically refractory disease
(9%), or with prior colectomy for UC and new intestinal
complaints (33%), or those with IBDU (17%), could be
reclassiﬁed as having CD based on the presence of typical
small-bowel ulcerations (deﬁned as the presence of 3 or
more ulcerations) seen at CE.8
In the setting of IBDU/IC, several studies on the ben-
eﬁt of CE for its evaluation have been published.6–8 These
small pilot studies found that the use of CE led to a change
in the diagnosis of 29%–40% of patients.6 A recent multi-
center study7 looked at 30 seronegative IBDU/IC patients
with a mean duration of disease of 6 years (range 1–18).
An initial CE was positive in 5 patients, with a mean dura-
tion of disease of 4 years (range 1–9), who were later diag-
nosed with CD. The remaining 25 patients, who had nega-
tive capsules, were then followed clinically for 7 years,
during which time CE was not repeated. Five more patients
were eventually diagnosed as having CD and 2 as having
UC, whereas the diagnosis of the other 18 patients
remained indeterminate. Patients with CD gained a reas-
sessment of their treatment. In the present study, CE
enabled the detection of small-bowel lesions diagnostic of
CD in 7 patients out of 18 with IC/IBDU (39%), leading to
a deﬁnitive diagnosis. We feel conﬁdent in the diagnosis of
CD in these patients since, in all cases, CE displayed
TABLE 3. CE Findings in the Small Bowel
Case Sex/ Age Initial Diagnosis
Capsule Endoscopy Findings
Final DiagnosisGroup Type Location
1 M/32 IC Group1 Normal — UC
2 M/45 IC Group1 Normal — IC
3 F/37 IC Group2 Focal villi denudation (FVD) Mid-small bowel IC
4 F/44 IC Group3 Erosion (n ¼ 8) Jejunum-ileal CD
5 F/32 IBDU Group2 Erosion (n ¼ 1) Mid-small bowel CD
6 F/39 IBDU Group2 Erosion* (n ¼ 2) Mid-small bowel IBDU
7 M/48 IBDU Group2 Erosion* (n ¼ 2) and FVD Mid-small bowel IBDU
8 F/59 IBDU Group2 Erosion (n ¼ 2) Mid-small bowel IBDU
9 F/20 IBDU Group2 Erosion* (n ¼ 2) Mid-small bowel IBDU
10 M/57 IBDU Group2 Erosion* (n ¼ 3) Mid-small bowel IBDU
11 M/32 IBDU Group2 Erosion* (n ¼ 3) and FVD Jejunum-ileal IBDU
12 F/28 IBDU Group2 Erosion* (n ¼ 3) and FVD Mid-small bowel IBDU
13 F/31 IBDU Group3 Ulcer (n ¼ 4) Ileal CD
14 F/32 IBDU Group3 Erosion (n ¼ 6) Jejunum-ileal CD
15 F/26 IBDU Group3 Erosion* (n ¼ 10) Jejunum-ileal CD
16 F/53 IBDU Group3 Erosion (n ¼ 3) and Ulcer (n ¼ 10) Jejunum-ileal CD
17 M/35 IBDU Group3 Erosion (n ¼ 38) and Ulcer (n ¼ 2) Jejunum-ileal CD
18 M/50 IBDU Group3 Erosion (n ¼ 77) and Ulcer (n ¼ 7) Jejunum-ileal CD
*Small erosion.
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excavated lesions described in the CE terminology that are
usually considered strongly suggestive of CD.9 However,
retrospectively, in none of them was the clinical strategy
changed by the knowledge of these ﬁndings, in contrast
with the previous study. This group showed a clinical het-
erogeneity ranging from asymptomatic with no medication
to chronic, continuous illness that requires immunosuppres-
sive drugs for its control.
Although a negative CE has a very high negative pre-
dictive value, we cannot exclude a diagnosis of CD. In
fact, CE presents false negatives22 caused by the miss rate
(11%), incomplete examination (in up to 25%), technical
limitations (battery life duration, ﬁeld of view), and subop-
timal cleanness of the small bowel (in up to 33%).
It must also be remembered that capsule examination
was not repeated in the present study and these patients
(most of them under treatment) may have macroscopic mu-
cosal abnormalities in the small intestine that can heal
completely and relapse later. Thus, despite a nonspeciﬁc
CE, 1 patient in the present series has evolved to a deﬁni-
tive diagnosis of CD during follow-up management, lead-
ing to a change in therapy.
It has often been emphasized that IBDU may be a
temporary diagnosis. Joossens et al5 showed that a deﬁni-
tive diagnosis of CD or UC within 6 years following dis-
ease onset was reached in 32% of patients. However, 40
(85%) of their 47 patients with IBDU and negative serol-
ogy remained indeterminate at follow-up. In our study,
50% of patients still have IBDU/IC, further emphasizing
the hypothesis that these patients with long-standing ‘‘inde-
terminate’’ disease and negative serology may belong to an
original subgroup of IBD.
These results conﬁrm the ambiguity in relation to the
real value of CE in this heterogeneous IBD group. Thus,
larger prospective studies are needed to conﬁrm its useful-
ness in this setting, as well as to standardize criteria for
CD at CE.
We conclude that, although in patients with long-
standing IBDU/IC and negative serology, CE can detect
small-bowel lesions which lead to a CD diagnosis in a sig-
niﬁcant proportion of patients (39% in our series), this ﬁnd-
ing did not bring about a modiﬁcation of the clinical man-
agement. Moreover, the single case in which a CD
diagnosis ultimately developed, leading to a change in ther-
apy, presented only subtle ﬁndings at CE examination. Our
results thus suggest that the capsule’s ﬁndings are not help-
ful in the clinical management of these patients.
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